Trending Topic

Acute myeloid leukaemia
3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

“We are facing an exciting era of fast-paced drug development in acute myeloid leukaemia” writes Gianfranco Bittar and colleagues at Baylor College of Medicine, Houston, TX, USA, in a review published in touchREVIEWS in Oncology & Haematology. In 2020, there were an estimated 21,450 new patients with acute myeloid leukaemia (AML) and 11,180 AML-related deaths […]

touchLearning Activities

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

 This interview features Dr Nico Gagelmann (University Medical Center Hamburg-Eppendorf, Hamburg, Germany) and Dr Claire Horgan (Royal Manchester Children's Hospital, Manchester, UK) co-chairs of the European Society for Blood and Marrow Transplantation (EBMT) Trainee Committee. Together, they discuss their motivations ...

Mark CompleteCompleted
BookmarkBookmarked

The 66th ASH Annual Meeting and Exposition is now just one week away! From December 7-10th 2024, San Diego, California is set to welcome over 30,000 health professionals, clinicians, researchers, educators and over 275 exhibitors, both in person and online, from around ...

Mark CompleteCompleted
BookmarkBookmarked

Prof. Pierre Fenaux, Head of the Department of  Hematology and Immunology at Assistance Publique-Hôpitaux de Paris Nord (Hôpitaux Saint-Louis, R Debré, Avicenne) is a leading expert in haematology with extensive experience in the treatment and management of myelodysplastic syndromes (MDS). In this interview, he discusses key considerations for first-line therapies in lower-risk MDS, the latest advances in treatment and the role of organizations like the European School of Hematology (ESH) in supporting haematologists.

Mark CompleteCompleted
BookmarkBookmarked

In this interview, Prof. Robin Foà, a distinguished haematologist and now Emeritus Professor of Haematology at the Sapienza University of Rome, Italy, shares the inspirations and career-defining moments that led him to focus on haematology and leukaemia research. Initially trained ...

50 mins
touchCONGRESS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Gianantonio Rosti, Dr Carla Boquimpani, Prof. Dr. med. Susanne Saussele

Watch this touchCONGRESS activity exploring advances in treatments for patients with CML, based on data from 2024 congresses, including EHA and ESH-iCMLf.

9 mins
Sponsored Content

Isatuximab is a CD38-receptor targeted monoclonal antibody approved as a combination therapy for the treatment of RRMM in patients who have received 1 to 3 lines of prior therapy.

Summary of Product Characteristics Link here
touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.

Mark CompleteCompleted
BookmarkBookmarked

A new study published in Blood explores the potential for successful pregnancy after allogeneic stem cell transplantation (allo-SCT), providing new hope for women who have undergone this intense treatment.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms (MPNs). In this episode, we speak with John Mascarenhas, MD, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.

Mark CompleteCompleted
BookmarkBookmarked

A recent review by Prof. Florence Pasquier and colleagues highlights the potential of olutasidenib, a selective, oral, small-molecule inhibitor of the mutant IDH1 enzyme, recently approved  by the FDA as treatment option for patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutations.

Mark CompleteCompleted
BookmarkBookmarked

The International Society on Thrombosis and Haemostasis (ISTH) has issued an evidence-based clinical practice guideline aimed at revolutionizing the treatment landscape for congenital haemophilia A and B. Hemophilia, a rare bleeding disorder caused by deficiencies in blood coagulation factors, affects individuals worldwide and demands intricate management strategies.

Mark CompleteCompleted
BookmarkBookmarked

The EHA 2024 congress has once again united top haematology experts from around the globe. This year's event featured plenty of innovations and developments, from novel therapies to cutting-edge genetic studies. In this article we provide an overview of the late-breaking abstracts presented at the meeting.

Mark CompleteCompleted
BookmarkBookmarked

Researchers at Vanderbilt University Medical Center (VUMC) have highlighted promising results from a phase II clinical trial for a new treatment for sickle cell disease (SCD). Published in Blood, the study aimed to achieve an 80% two-year event-free survival rate following a specific bone marrow transplant (BMT) method. The international trial, led by Dr DeBaun and Dr Adetola Kassim, involved 32 children and 38 adults from five countries.

Mark CompleteCompleted
BookmarkBookmarked

We’re looking forward to the EHA 2024 Hybrid Congress which is taking place in Madrid, between 13-16 June 2024.  Promising attendees the opportunity to explore the latest advancements in haematology, including cutting-edge technologies, treatments, and products. The focus will encompass a ...

22 mins

Watch leading experts Shaji Kumar and Rahma Warsame discuss the current and evolving treatment landscape in relapsed/refractory multiple myeloma, as well as key factors influencing treatment decisions.

33 mins
touchEXPERT OPINIONS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Andrew Wei, Prof. Agnieszka Wierzbowska, Prof. Gert Ossenkoppele

Experts answer questions with in-depth advice on the current clinical landscape and how new guidelines might impact regional clinical practice. Useful tips below will show how to navigate the activity.

62 mins
touchSATELLITE SYMPOSIUM
Mark CompleteCompleted
BookmarkBookmarked
Prof. Susanne Saussele, Prof. Massimo Breccia, Prof. Valentín García Gutiérrez

Three experts consider unmet needs in chronic myeloid leukaemia and how new and emerging treatments may help address them.

29 mins
touchIN CONVERSATION
Mark CompleteCompleted
BookmarkBookmarked

Two specialists in chronic myeloid leukaemia (CML) discuss the mechanisms of action and latest data for current and emerging treatments and how they may impact the management of CML after two prior lines of therapy.

Load More...
touchHAEMATOLOGY touchHAEMATOLOGY

Register Now!

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

  • Save your progress for video
  • Keep track of your CME credits
  • Add personalised learning notes
  • Receive updates from course leaders and faculty
  • Be the first to hear about new and exciting interactive learning opportunities
Close Popup